Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Preveceutical Medical Inc C.PREV

Alternate Symbol(s):  PRVCF

Healthcare Biotechnology
PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is a cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its Dual Gene Therapy for curative and prevention therapies for diabetes and obesity. Its Nature Identical peptides for treatment of various ailments. Its BSV peptide program targets cancer progression. Its nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).


CSE:PREV - Post by User

Preveceutical Medical Inc
Bullboard Posts
User Avatar Image
(251)
•••
Comment by CanadaCoinon Aug 06, 2019 4:05pm
84 Views
Post# 29998958

RE:Making due

RE:Making due
Wantsomenuts wrote: So what are the possibilities for success from this move? If everyone's chiming in about why it's so bad...Who's the successor of the deal? Any one want to take this question on with a devils-advocate opinion would be clutch


Let's look at it this way. Because Asterion is a private company, Assterion is basiclly Van Deventer. And here is what PREV's President said about the news....

PreveCeutical's President and Chief Science Officer, Dr. Mak Jawadekar, stated, "This option agreement presents a unique and timely opportunity for PreveCeutical. We are excited to further our existing strategic partnership with Asterion and are confident that Asterion will assist PreveCeutical in the rapid commercialisation of the Sol-Gel IP."

So, if Van Deventer is willing to assist PreveCeutical in the rapid commercialisation of Sol-Gel at Asterion, why is he not willing to assist PreveCeutical in the same commercialisation while is it fully held by PREV? Is he commited to PREV or not...is the question? 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities